BRANDED DRUG MAKERS RAISE CONCERNS ABOUT BIOLOGICS
Representatives of the brand namepharmaceutical industry told Congressthat current pending legislation toaccelerate the marketing of generic"follow-on"biologics could create a"significant risk"for public safety "dueto the significant differences betweenbiologic products from different manufacturers."A key problem, according tothe Pharmaceutical Research andManufacturers of America (PhRMA), isthat "follow-on biologics are not identicalto innovator biologics."
PhRMA said that its members standready to support the establishment of aregulatory pathway for follow-on biologics,but only "if patient safety can beassured and the innovation of futuremedicines is not compromised."Althoughgeneric drug manufacturers arenot required to conduct clinical trials tosecure FDA marketing approval for theirregular "small-molecule"generic pharmaceuticals,such studies should berequired before generic biologics areapproved, PhRMA officials said.
Significantly, however, none of thepending bills addressing follow-on biologicswould require such testing. "Webelieve that unless clinical trials areconducted to show the safety andeffectiveness of follow-on biologics?patients would have no assurance thatthe product they are taking is safe,"PhRMA said.
The branded drug group also raisedconcerns that the pending legislation"would allow a follow-on biologic to bereplaced with a similar product—but aproduct with a potentially differentmakeup—at pharmacies, hospitals, andphysician offices. It is troubling to thinkthat physicians would not knowwhether their patients are receiving thespecific biologic treatment they prescribed,or a similar product that couldhave very different effects on thepatient,"PhRMA said.
Articles in this issue
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
- Evaluation of Pharmacist-Driven Penicillin Allergy Reconciliation
September 17th 2025
- Pharmacists Can Apply Their Expertise to the Medical Psilocybin Act
September 16th 2025
- From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy Research
September 15th 2025